These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 2692689)

  • 1. Organising clinical research: 3. Trial design.
    Mapleson WW
    Br J Clin Pract; 1989 Mar; 43(3):89-93. PubMed ID: 2692689
    [No Abstract]   [Full Text] [Related]  

  • 2. Overhauling clinical trials.
    Scott CT; Baker M
    Nat Biotechnol; 2007 Mar; 25(3):287-92. PubMed ID: 17344876
    [No Abstract]   [Full Text] [Related]  

  • 3. Design and analysis of prostate cancer trials.
    Sylvester R
    Acta Urol Belg; 1994 Apr; 62(1):23-9. PubMed ID: 8197926
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical trial design issues in schizophrenic research.
    Casey DE
    J Clin Psychiatry; 2001; 62 Suppl 9():17-20; discussion 21-2. PubMed ID: 11379826
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A primer on the design, conduct, and interpretation of clinical trials.
    Appel LJ
    Clin J Am Soc Nephrol; 2006 Nov; 1(6):1360-7. PubMed ID: 17699370
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FDA perspective on clinical trial design for cardiovascular devices.
    Chen E; Sapirstein W; Ahn C; Swain J; Zuckerman B
    Ann Thorac Surg; 2006 Sep; 82(3):773-5. PubMed ID: 16928481
    [No Abstract]   [Full Text] [Related]  

  • 7. The clinician as investigator: participating in clinical trials in the practice setting: Appendix 1: fundamentals of study design.
    Lader EW; Cannon CP; Ohman EM; Newby LK; Sulmasy DP; Barst RJ; Fair JM; Flather M; Freedman JE; Frye RL; Hand MM; Jesse RL; Van de Werf F; Costa F;
    Circulation; 2004 Jun; 109(21):e302-4. PubMed ID: 15173052
    [No Abstract]   [Full Text] [Related]  

  • 8. Does study design explain the relationship between conflict of interest and positive outcome in clinical trials in psychiatry?
    Wu Y; Deboeck P; Joseph M; Hwang C; Perlis CS; Perlis RH
    J Clin Psychopharmacol; 2009 Dec; 29(6):609-11. PubMed ID: 19910733
    [No Abstract]   [Full Text] [Related]  

  • 9. Research in general practice in New Zealand.
    Reid J
    N Z Med J; 2003 Nov; 116(1186):U679. PubMed ID: 14657962
    [No Abstract]   [Full Text] [Related]  

  • 10. Design and endpoints of clinical trials in hepatocellular carcinoma.
    Llovet JM; Di Bisceglie AM; Bruix J; Kramer BS; Lencioni R; Zhu AX; Sherman M; Schwartz M; Lotze M; Talwalkar J; Gores GJ;
    J Natl Cancer Inst; 2008 May; 100(10):698-711. PubMed ID: 18477802
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The clinician as investigator: participating in clinical trials in the practice setting: Appendix 2: statistical concepts in study design and analysis.
    Lader EW; Cannon CP; Ohman EM; Newby LK; Sulmasy DP; Barst RJ; Fair JM; Flather M; Freedman JE; Frye RL; Hand MM; Jesse RL; Van de Werf F; Costa F;
    Circulation; 2004 Jun; 109(21):e305-7. PubMed ID: 15173053
    [No Abstract]   [Full Text] [Related]  

  • 12. The value of information and optimal clinical trial design.
    Willan AR; Pinto EM
    Stat Med; 2005 Jun; 24(12):1791-806. PubMed ID: 15806619
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incorporating intermediate binary responses into interim analyses of clinical trials: a comparison of four methods.
    Whitehead A; Sooriyarachchi MR; Whitehead J; Bolland K
    Stat Med; 2008 May; 27(10):1646-66. PubMed ID: 17886243
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical trial design issues: at least 10 things you should look for in clinical trials.
    Glasser SP; Howard G
    J Clin Pharmacol; 2006 Oct; 46(10):1106-15. PubMed ID: 16988199
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Global benefit-risk assessment in designing clinical trials and some statistical considerations of the method.
    Pritchett YL; Tamura R
    Pharm Stat; 2008; 7(3):170-8. PubMed ID: 17538942
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Open-label surgical trials for Parkinson disease: time for reconsideration.
    Alterman RL; Tagliati M; Olanow CW
    Ann Neurol; 2011 Jul; 70(1):5-8. PubMed ID: 21786295
    [No Abstract]   [Full Text] [Related]  

  • 17. [The importance of equivalence trials in showing the usefulness of treatments].
    Hermens ML; van Hout HP; Terluin B; Adèr HJ; de Haan M
    Ned Tijdschr Geneeskd; 2003 Nov; 147(44):2162-6. PubMed ID: 14626832
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical trials of novel and targeted therapies: endpoints, trial design, and analysis.
    Suman VJ; Dueck A; Sargent DJ
    Cancer Invest; 2008 Jun; 26(5):439-44. PubMed ID: 18568764
    [No Abstract]   [Full Text] [Related]  

  • 19. Design and analysis of a randomized controlled trial testing the effects of clinical decision support on the management of rheumatoid arthritis.
    Fransen J; Twisk JW; Creemers MC; van Riel PL
    Arthritis Rheum; 2004 Feb; 51(1):124-7. PubMed ID: 14872465
    [No Abstract]   [Full Text] [Related]  

  • 20. Randomization as a basis for inference in noninferiority trials.
    Wiens BL
    Pharm Stat; 2006; 5(4):265-71. PubMed ID: 17128425
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.